How GLP-1 clinics can reduce patient dropout

GLP-1 discontinuation is a real clinical problem. Studies suggest 30-50% of patients stop within six months — often during the titration phase, when side effects peak and results are not yet visible.

Why patients drop out

The three most common reasons are unmanaged side effects, cost anxiety, and feeling unsupported between appointments. The third is the one clinics can address directly.

Patients who have no structured way to log what they are experiencing tend to interpret normal titration effects as failure. Without a framework, nausea at week 3 reads as 'this medication doesn't work' rather than 'this is the dose-adjustment window.'

What structured follow-up changes

Clinics that provide patients with a tracking structure — even a simple weekly log — see meaningfully better engagement past the 60-day mark. The mechanism is not mystery: patients who can report specific data at each visit feel heard, get better-calibrated titration decisions, and understand their progress in terms beyond the scale.

The referral model

A clinic partner referral costs nothing to give a patient. A QR code at checkout, a short explanation from the prescribing physician, and a 7-day free trial removes every barrier to adoption. The outcome data comes back to the practice monthly in aggregate — no HIPAA complexity, no individual patient records, no new software to learn.

The patients who stay on GLP-1s long enough to see results are the ones who feel supported. That support does not have to come entirely from the clinic — it just has to come from somewhere.